Department of Medicine

Cardiovascular Medicine Faculty

Rhonda M. Cooper-DeHoff, Pharm D, MS Division of Cardiovascular Medicine Research Associate Professor Associate Director, Cardiovascular Clinical Research Program e-mail:dehofrm@medicine.ufl.edu 1600 SW Archer Road/Box 100277 Gainesville, FL 32610-0277 (352) 392-6388/FAX (352) 846-3451

Dr. Cooper-DeHoff graduated from the University of California at San Francisco, School of Pharmacy in 1986 and completed a residency there in 1987. In 2007, she graduated from the University of Florida with a master’s degree in medical sciences, with an emphasis in clinical investigation. Her interests are in coronary artery disease and hypertension and the adverse metabolic effects of antihypertensive medications.

Training:

Academic Interests:

Dr. Cooper-DeHoff is the principal investigator for the NIH-funded study “Metabolic Effects of Antihypertensive Drugs”. She was also an investigator of the International Verapamil Trandolapril Study (INVEST) which evaluated hypertension treatments in elderly coronary artery disease patients, and is a co-investigator on two NIH grants evaluating pharmacogenetic associations in hypertension. She has completed participation in the Advanced Postgraduate Program in Clinical Investigation (NIH-funded K30 program) at the University of Florida. She is a member of the American Heart Association, American Society of Hypertension, American College of Cardiology and Florida Society of Hospital Pharmacists.

Clinical Interests:

Hypertension, Pharmacology, Pharmacogenetics, Diabetes, Metabolic Syndrome, Coronary Artery Disease

Representative Publications:

1. Cooper-DeHoff RM, Handberg E, Heissenberg, C, Johnson, K. Electronic prescribing via the internet for a coronary artery disease and hypertension megatrial. Clin Cardiol 2001;24(11):V14-V16.
2. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The INternational VErapamil-Trandolapril STudy (INVEST). JAMA 2003;290(21):2805-2816.
3. Cooper-DeHoff RM, Handberg EM, Cohen J, Kowey P, Messerli F. Characteristics of contemporary patients with hypertension and coronary artery disease. Clin Cardiol. 2004;27(10):571-576.
4. Cooper-DeHoff RM, Pepine CJ. Editorial: Ranolazine is associated with cardiovascular and metabolic improvement: A win-win for patients with diabetes. Eur Heart J 2006;27(1):5-6.
5. Cooper-DeHoff RM, Aranda JM, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ. Blood pressure control and cardiovascular outcomes in high risk Hispanic patients – Findings from the International Verapamil SR – Trandolapril Study. Am Heart J 2006;151:1079-86.
6. Cooper-DeHoff RM, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ, for the INVEST Investigators. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications: Findings from the INternational VErapamil SR-trandolapril STudy (INVEST). Am J Cardiol 2006;98(7):890-894.
7. Cooper-DeHoff RM, Zhou Q, Gaxiola E, Cangiano JL, Garcia-Barreto D, Handberg E, Pepine CJ, for the INVEST investigators. Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: Findings from INVEST. J Womens Health 2007;16(5):632-640.